Approximately 15–20% of breast cancer cases are characterized by the overexpression of human epidermal growth factor receptor 2 (HER2) (Siegel et al., 2014; Loibl and Gianni, 2017). This evidence concerns the gene ERBB2 and breast carcinoma.